**United Kingdom of Great Britain and Northern Ireland**

**Tuberculosis profile**

Population 2018: 67 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>5.4 (4.8–5.9)</td>
<td>8 (7.2–8.8)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.15 (0.12–0.18)</td>
<td>0.23 (0.18–0.27)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.093 (0.062–0.13)</td>
<td>0.14 (0.09–0.19)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>0.3 (0.3–0.31)</td>
<td>0.45 (0.45–0.46)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.023 (0.015–0.031)</td>
<td>0.03 (0.02–0.05)</td>
</tr>
</tbody>
</table>

| Estimated proportion of TB cases with MDR/RR-TB, 2018 |
|-----------------------------|-------------------|
| New cases                   | 1.2% (0.8–1.8)    |
| Previously treated cases    | 5.3% (2.3–10)     |

**TB case notifications, 2018**

- Total new and relapse: 4,775
  - % tested with rapid diagnostics at time of diagnosis: 8%
  - % with known HIV status: 85%
  - % pulmonary: 58%
  - % bacteriologically confirmed: 78%
  - % children aged 0–14 years: 3%
  - % women: 40%
  - % men: 57%

- Total cases notified: 5,075

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018: 99% (81–98)
- TB patients facing catastrophic total costs
  - TB case fatality ratio (estimated mortality/estimated incidence), 2018: 6% (6–7)

**TB/HIV care in new and relapse TB patients, 2018**

- Patients with known HIV status who are HIV-positive: 115 (3%)
  - on antiretroviral therapy: 100 (87%)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 94%
  - New cases: 94%
  - Previously treated cases: 93%

**Laboratory-confirmed cases**

- MDR/RR-TB: 49, XDR-TB: 4

**Patients started on treatment**

- MDR/RR-TB: 45, XDR-TB: 4

**MDR/RR-TB cases tested for resistance to second-line drugs**

- 42

**Treatment success rate and cohort size**

- New and relapse cases registered in 2017: 81% (5176)
- Previously treated cases, excluding relapse, registered in 2017: 76% (301)
- HIV-positive TB cases registered in 2017: 73% (136)
- MDR/RR-TB cases started on second-line treatment in 2016: 66% (59)
- XDR-TB cases started on second-line treatment in 2016: 43% (7)

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

**TB financing, 2019**

- National TB budget (US$ millions)

*Ranges represent uncertainty intervals
MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
Calculated for pulmonary cases only
Includes cases with unknown previous TB treatment history
Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed